Digoxin
Lanoxin (digoxin) is a small molecule pharmaceutical. Digoxin was first approved as Lanoxin on 1982-01-01. It is used to treat anxiety disorders, atrial fibrillation, atrial flutter, cardiogenic shock, and heart failure amongst others in the USA. The pharmaceutical is active against sodium/potassium-transporting ATPase subunit alpha-1. In addition, it is known to target solute carrier organic anion transporter family member 4C1.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Lanoxin (generic drugs available since 1982-01-01, discontinued: Lanoxicaps)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Digoxin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LANOXIN | Concordia Laboratories | N-020405 RX | 1997-09-30 | 3 products, RLD, RS |
| LANOXIN | Covis Pharma | N-009330 RX | 1982-01-01 | 1 products, RLD, RS |
| LANOXIN PEDIATRIC | Covis Pharma | N-009330 RX | 1982-01-01 | 1 products, RLD, RS |
| DIGOXIN | Hikma Pharmaceuticals | N-021648 RX | 2004-08-26 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lanoxin | New Drug Application | 2022-11-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| anxiety disorders | EFO_0006788 | D001008 | F41.1 |
| atrial fibrillation | EFO_0000275 | D001281 | I48.0 |
| atrial flutter | EFO_0003911 | D001282 | — |
| cardiogenic shock | — | D012770 | R57.0 |
| heart failure | EFO_0003144 | D006333 | I50 |
| low cardiac output | — | D002303 | — |
| supraventricular tachycardia | HP_0004755 | D013617 | I47.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
172 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 53 | — | — | 1 | — | 54 | ||
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | — | 5 | 4 | 4 | 14 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | 3 | 6 | 2 | 11 |
| Dilated cardiomyopathy | D002311 | EFO_0000407 | I42.0 | — | — | — | 1 | — | 1 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | 1 | — | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | — | 1 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 2 | — | 1 | 3 |
| Supraventricular tachycardia | D013617 | HP_0004755 | I47.1 | — | — | 2 | — | 1 | 3 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 2 | — | — | 2 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | 2 | 1 | — | — | 2 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | — | 1 |
| Atrial flutter | D001282 | EFO_0003911 | — | — | 1 | — | — | 1 | |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 4 | 1 | — | — | — | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 2 | — | — | — | 4 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 2 |
| Prostatic neoplasms | D011471 | C61 | 1 | 1 | — | — | — | 2 | |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 1 | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | D46 | 1 | 1 | — | — | — | 1 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 1 | — | — | — | 1 | |
| Head and neck neoplasms | D006258 | 1 | 1 | — | — | — | 1 | ||
| Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | — | 1 | ||
| Actinic keratosis | D055623 | L57.0 | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 9 | — | — | — | — | 9 | |
| Drug interactions | D004347 | 7 | — | — | — | — | 7 | ||
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 5 | — | — | — | — | 5 |
| Melanoma | D008545 | 2 | — | — | — | — | 2 | ||
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | — | — | — | — | 2 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | 2 | — | — | — | — | 2 | ||
| Hereditary angioedemas | D054179 | EFO_0004131 | 1 | — | — | — | — | 1 | |
| Vomiting | D014839 | HP_0002013 | R11.1 | 1 | — | — | — | — | 1 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | 1 | — | — | — | — | 1 |
Show 19 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Induced abortion | D000028 | — | — | — | — | 3 | 3 | ||
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | — | — | — | 1 | 1 |
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | 1 | 1 | |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
| Medullary thyroid cancer | C536914 | — | — | — | — | 1 | 1 | ||
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DIGOXIN |
| INN | digoxin |
| Description | Digoxin is a cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small. It has a role as an epitope, an anti-arrhythmia drug, a cardiotonic drug and an EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor. It is a cardenolide glycoside and a steroid saponin. It is a conjugate acid of a digoxin(1-). |
| Classification | Small molecule |
| Drug class | fluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O |
Identifiers
| PDB | 7DDH |
| CAS-ID | 20830-75-5 |
| RxCUI | 3407 |
| ChEMBL ID | CHEMBL1751 |
| ChEBI ID | 4551 |
| PubChem CID | 2724385 |
| DrugBank | DB00390 |
| UNII ID | 73K4184T59 (ChemIDplus, GSRS) |
Target
Agency Approved
ATP1A1
ATP1A1
Organism
Homo sapiens
Gene name
ATP1A1
Gene synonyms
NCBI Gene ID
Protein name
sodium/potassium-transporting ATPase subunit alpha-1
Protein synonyms
ATPase, Na+/K+ transporting, alpha 1 polypeptide, Na(+)/K(+) ATPase alpha-1 subunit, Na+/K+ ATPase 1, Na, K-ATPase, alpha-A catalytic polypeptide, Na,K-ATPase alpha-1 subunit, Na,K-ATPase catalytic subunit alpha-A protein, Sodium pump subunit alpha-1, sodium-potassium ATPase catalytic subunit alpha-1, sodium-potassium-ATPase, alpha 1 polypeptide
Uniprot ID
Mouse ortholog
Atp1a1 (11928)
sodium/potassium-transporting ATPase subunit alpha-1 (Q91Z09)
Alternate
SLCO4C1
SLCO4C1
Organism
Homo sapiens
Gene name
SLCO4C1
Gene synonyms
OATP4C1, OATPX, SLC21A20
NCBI Gene ID
Protein name
solute carrier organic anion transporter family member 4C1
Protein synonyms
OATP-H, OATP-M1, OATP4C1, Organic anion transporter M1, Organic anion transporting polypeptide 4C1, Solute carrier family 21 member 20
Uniprot ID
Mouse ortholog
Slco4c1 (227394)
solute carrier organic anion transporter family member 4C1 (Q8BGD4)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 28,602 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
59,282 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more